<?xml version="1.0" encoding="utf-8" ?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Pharmalicensing.com: PR Newswire: Investment Opinions</title>
		<link>http://pharmalicensing.com/rss/</link>
		<description>Latest market and business intelligence from the leading publishers worldwide.</description>
		<language>en-us</language>
		<image>
			<title>Pharmalicensing.com: PR Newswire: Investment Opinions</title>
			<link>http://pharmalicensing.com/rss/</link>
			<url>http://pharmalicensing.com/images/pharmalicensing_logo.gif</url>
			<width>144</width>
		</image>
									<item>
				<title>Personalised Medicine: An Opportunity for Investment</title>
				<description>LONDON, January 14 /PRNewswire/ -- The pharmaceutical industry is currently facing some key challenges. The
increase in drug development costs, a decrease in the number of drugs being
approved, and...</description>
				<link>http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2408</link>
				<guid>http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2408</guid>
				<pubDate>Wed, 14 Jan 2009 11:45:00 +0000</pubDate>
			</item>
						<atom:link href="http://pharmalicensing.com/public/public/news/newsmlrss/267/Investment_Opinions" rel="self" type="application/rss+xml" />
	</channel>
</rss>
